News
News Releases
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Remains on Track to Dose First Subjects in Q2 2021
Vancouver, Canada. April 14, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee (“HREC”) in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma (“PTPσ”) inhibitor.
NervGen Pharma Reports 2020 Year End Results
Vancouver, Canada. April 8, 2021– NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.
NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
NervGen Pharma Provides Regulatory Update on Development Program for NVG-291
Plans to Dose First Human Subjects in Phase 1 in Q2 2021
NervGen Pharma Adds Alzheimer’s Disease Patient Cohort to its Phase 1 Clinical Trial Program
NervGen Pharma Establishes Alzheimer’s Disease Scientific Advisory Board
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer’s Disease Program
NervGen Renews Business Advisory Relationship with Brian McAlister
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-dilutive Funding Sources for NVG-291
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
NervGen Pharma Announces Annual General Meeting and Company Update to be Held on September 30, 2020
NervGen Pharma Announces Departure of Chief Operating Officer
LifeSci Advisors Engaged to Provide Investor Relations Services
NervGen Pharma Reports Second Quarter 2020 Results
Phase 1 Clinical Study Remains on Track for Q4 2020
NervGen Pharma Corp. Completes $6.45 Million Public Offering
NervGen Pharma Corp. Announces Upsizing of Financing and Filing of Amended and Restated Prospectus Supplement
NervGen Pharma Corp. Announces Filing of Prospectus Supplement
NervGen Pharma Announces Pricing of Public Offering
NervGen Pharma Corp. Announces Public Offering
NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
Ohio Department of Higher Education Awards $250,000 Grant to Dr. Jerry Silver, Co-inventor of NervGen’s Lead Compound
NervGen Pharma Grants Stock Options
NervGen Pharma Reports First Quarter 2020 Results
Phase 1 Clinical Trial Remains on Track for Q4 2020
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NervGen Pharma Reports 2019 Year End Results
Phase 1 Clinical Study Remains on Track for Q4 2020
NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic
Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th
Phase 1 Clinical Study Remains on Track for Q4 2020
NervGen Pharma Provides a Development Update on its Lead Product NVG-291
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
NervGen Pharma Responds To Recent Increase In Market Activity
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer / Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
NervGen Receives Investment from Drug Manufacturing Partner / CSBio Invests US$1,500,000 As Part of Manufacturing Contract For Clinical Trial Product
NervGen Pharma Expands Platform Into Alzheimer’s Disease / NervGen Pharma’s NVG-291 Compound on Track to Begin Phase 1 in Q1 2020
NervGen Pharma Announces Clinical Development Plan For the Treatment of Nerve Damage and Neurodegenerative Diseases / NervGen Reports Results of Annual General Meeting of Shareholders
NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper
NervGen Amends Investor Relations Agreement
NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination / Lead Indication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial
NervGen Pharma Announces Upgrade to the OTCQX® Best Market in the U.S.
NervGen Pharma Presenting at the 9th Annual LD Micro Invitational
NervGen Pharma Engages Torrey Hills Capital for Investor Relations
NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing / Paul Brennan Joins NervGen Pharma as Business Advisor
NervGen Pharma Commences Trading on OTCQB / NervGen Pharma Engages Market Maker
NervGen Pharma to Ring the Opening Bell of Toronto Stock Exchange / NervGen Pharma Closes Private Placement
NervGen Pharma’s Patent Estate Grows with the Addition of US Patents for its Groundbreaking Nerve Regeneration Technology
NervGen Pharma Increases Private Placement to $740,000
NervGen Pharma Appoints Amy Franke as VP, Clinical Operations
NervGen Pharma Announces $500,00 Private Placement
NervGen Pharma Completes $10 Million Initial Public Offering / Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
NervGen Pharma Appoints Dr. Michael Abrams to Board of Directors
NervGen Announces Granting of US Patent for Breakthrough Nerve Regeneration Technology
NervGen Licenses Breakthrough Nerve Regeneration Technology from Case Western Reserve University
NervGen Appoints Dr. Ernest Wong as President & CEO
Articles
NervGen CFO: Dig Into Strategy
StrategicCFO360
November 9, 2020
StrategicCFO360 interviews Bill Adams about about how he manages a broadening role in a small, but fast growing biotech.
Industry Matters: NervGen Targets Glial Scars to Treat Alzheimer’s
Scientific Inquirer
November 5, 2020
Scientific Inquirer interviews Paul Brennan about the company’s technology and bright future.
Releasing the Handbrake on Endogenous Repair – An Alternate Approach to Treating Alzheimer’s Disease
Technology Networks
January 13, 2020
Technology Networks speaks with Paul Brennan to gain his insights on previous attempts to treat Alzheimer’s disease, how NVG-291 works, and what promise it hold for Alzheimer’s disease.
Emerging Treatments for Spinal Cord Damage
A Real Growing Concern
Injectable Peptide Might Help Spinal Cord Injury Patients Walk Again
Spinal Cord Damage and Emerging Treatments
“Inhibiting the Inhibitors” to Support Axonal Regeneration
OHSU Researchers Discover Peptide That Can Penetrate Heart Attack Scar Tissue, Regenerate Cardiac Nerves
Rats with Spinal Cord Injury Regain Bladder Function and Some Mobility Following Injection with Novel Drug
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
The results demonstrate how fundamental laboratory research may lead to new therapies. “We’re very excited at the possibility that millions of people could, one day, regain movements lost during spinal cord injuries,” said Jerry Silver, Ph.D.
Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.
Peptide Helps Paralyzed Rats Recover Function
Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.
Intracellular Sigma Peptide: Breakthrough Drug May Heal Damaged Spines
For the first time, scientists may have found a drug that can help heal a damaged spine and restore some movement and bladder control.Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.